Skip to content

Xenogenic Collagen Matrix for the Treatment of Multiple Gingival Recessions

Coronally Advanced Flap With Xenogenic Collagen Matrix or Autogenous Connective Tissue Graft for the Treatment of Multiple Adjacent Gingival Recessions: a Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05693753
Enrollment
40
Registered
2023-01-23
Start date
2023-02-02
Completion date
2024-12-02
Last updated
2023-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gingival Recession, Generalized

Brief summary

The primary aim of this study is to evaluate whether the use of a xenogenic collagen matrix (XCM) for the treatment of multiple adjacent gingival recessions (MAGRs) with a multiple coronally advanced flap technique (mCAF) achieves better results than the use of an autologous connective tissue graft (CTG) in terms of recession reduction (primary outcome) and other secondary root coverage outcomes (e.g. complete root coverage, mean root coverage). Moreover, this study aims to compare secondary clinical variables (e.g. keratinized tissue width (KTW) changes, probing pocket depth (PPD) changes, volumetric gain (VG), etc.), also with a digital approach, the patient-reported outcome measures (PROMs e.g. pain, swelling, bleeding). The hypothesis of this study is that at 6 months and 1 year follow-up the mCAF with XCM is not inferior to CTG in terms of recessions reduction and secondary clinical variables, and superior regarding to PROMs.

Interventions

DEVICEUse of XCM for the treatment of MAGRs with mCAF technique

After local anaesthesia, mCAF technique will be performed. XCM will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction.

PROCEDURETreatment of MAGRs with CTG

After local anaesthesia, mCAF technique will be performed. CTG will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction.

Sponsors

University of Turin, Italy
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* At least 18 years old and able to sign informed consent * At least 2 adjacent teeth with RT1 and/or RT2 gingival recessions without interproximal exposure of the CEJ (interdental gingival recession), at least one with a depth of ≥2mm with indication for root coverage treatment * A minimum of 4 adjacent teeth (including the ones to be treated) in the region of interest * Available to attend study related procedures (including follow-up visits)

Exclusion criteria

* Systemic diseases/medications which could influence the outcome of the therapy (e.g., uncontrolled diabetes mellitus); * Current smokers (self-reported, any type of smoking), users of chewing tobacco, and drug/alcohol abusers; * Pregnant or nursing women; * History of previous periodontal surgery (mucogingival or other) on the teeth to be included; * Furcation involvement in the teeth to be included; * Presence of severe tooth malposition, rotation or clinically significant extrusion in the teeth to be treated; * Presence of fixed or removable prosthesis in the area to be treated

Design outcomes

Primary

MeasureTime frameDescription
Mean Recession Reduction (RecRed)6 months; 1 yearMean changes in mm in recession depth between baseline and 1-year

Secondary

MeasureTime frameDescription
Complete Root Coverage (CRC)6 months; 1 yearPercentage of sites with complete root coverage after 1-year
Mean Root Coverage (MRC)6 months; 1 yearPercentage of mean root coverage after 1-year
Keratinised tissue height (KTH) changes6 months; 1 yearLinear changes in mm from the gingival margin to the mucogingival junction between baseline and 1-year
Post-operative morbidity (pain, swelling, discomfort)14 daysAssessment of patient's pain, swelling and discomfort at 14 days after the procedure using visual analogue scale (VAS) ranging from 0 (no pain, swelling or discomfort) to 10 (maximum pain, swelling or discomfort) with a questionnaire

Countries

Italy

Contacts

Primary ContactMario Aimetti, MD
mario.aimetti@unito.it0116331546

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026